^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Topoisomerase II-beta inhibitor

    Related drugs:
    28d
    Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, Moleculin Biotech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    liposomal annamycin (L-ANN)
    2ms
    Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases (clinicaltrials.gov)
    P1/2, N=36, Completed, Moleculin Biotech, Inc. | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: May 2024 --> Aug 2024
    Trial completion • Phase classification • Trial completion date
    |
    liposomal annamycin (L-ANN)